Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
4
×
boston top stories
national blog main
national top stories
4
×
san francisco blog main
san francisco top stories
biotech
life sciences
new york blog main
new york top stories
abeona therapeutics
affordable care act
agios pharmaceuticals
alirocuma
alzheimer's
ameet nathwani
arches
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
david schenkein
deals
debate
detroit blog main
detroit top stories
digital
donald trump
drug price
econmoic impact
elimination
fda
food and drug administartion
georgia
glioblastoma
gv
iclaprim
indiana blog main
indiana top stories
international price index
jim greenwood
What
based
4
×
bio
american
best
continue
crash
debate
healthcare
industry
kind
nash
people
pharmaceutical
policy
politicians
pressure
roundup
scalps
trump’s
u.s
aims
approach
available
big
biosciences
biotech
called
cas
cheaper
crispr
debuts
develop
developing
diagnostics
drugs
epigenetic
epigenetics
expects
faster
field
Language
unset
Current search:
xconomy.com
×
based
×
" boston blog main "
×
" national top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
